IL153707A0 - Carbamates derived from arylalkylamines - Google Patents

Carbamates derived from arylalkylamines

Info

Publication number
IL153707A0
IL153707A0 IL15370701A IL15370701A IL153707A0 IL 153707 A0 IL153707 A0 IL 153707A0 IL 15370701 A IL15370701 A IL 15370701A IL 15370701 A IL15370701 A IL 15370701A IL 153707 A0 IL153707 A0 IL 153707A0
Authority
IL
Israel
Prior art keywords
arylalkylamines
carbamates derived
carbamates
derived
Prior art date
Application number
IL15370701A
Other languages
English (en)
Original Assignee
S A L V A T Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8494130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL153707(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by S A L V A T Lab Sa filed Critical S A L V A T Lab Sa
Publication of IL153707A0 publication Critical patent/IL153707A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03B—APPARATUS OR ARRANGEMENTS FOR TAKING PHOTOGRAPHS OR FOR PROJECTING OR VIEWING THEM; APPARATUS OR ARRANGEMENTS EMPLOYING ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ACCESSORIES THEREFOR
    • G03B27/00—Photographic printing apparatus
    • G03B27/02—Exposure apparatus for contact printing
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03B—APPARATUS OR ARRANGEMENTS FOR TAKING PHOTOGRAPHS OR FOR PROJECTING OR VIEWING THEM; APPARATUS OR ARRANGEMENTS EMPLOYING ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ACCESSORIES THEREFOR
    • G03B27/00—Photographic printing apparatus
    • G03B27/02—Exposure apparatus for contact printing
    • G03B27/14—Details
    • G03B27/16—Illumination arrangements, e.g. positioning of lamps, positioning of reflectors
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03B—APPARATUS OR ARRANGEMENTS FOR TAKING PHOTOGRAPHS OR FOR PROJECTING OR VIEWING THEM; APPARATUS OR ARRANGEMENTS EMPLOYING ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ACCESSORIES THEREFOR
    • G03B27/00—Photographic printing apparatus
    • G03B27/02—Exposure apparatus for contact printing
    • G03B27/14—Details
    • G03B27/30—Details adapted to be combined with processing apparatus
    • G03B27/303—Gas processing
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03D—APPARATUS FOR PROCESSING EXPOSED PHOTOGRAPHIC MATERIALS; ACCESSORIES THEREFOR
    • G03D13/00—Processing apparatus or accessories therefor, not covered by groups G11B3/00 - G11B11/00
    • G03D13/002—Heat development apparatus, e.g. Kalvar
IL15370701A 2000-06-27 2001-06-25 Carbamates derived from arylalkylamines IL153707A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200001661 2000-06-27
PCT/ES2001/000252 WO2002000652A1 (es) 2000-06-27 2001-06-25 Carbamatos derivados de arilalquilaminas

Publications (1)

Publication Number Publication Date
IL153707A0 true IL153707A0 (en) 2003-07-06

Family

ID=8494130

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15370701A IL153707A0 (en) 2000-06-27 2001-06-25 Carbamates derived from arylalkylamines

Country Status (30)

Country Link
US (2) US6916828B2 (es)
EP (1) EP1300407B2 (es)
JP (1) JP5046465B2 (es)
KR (1) KR100751981B1 (es)
CN (1) CN1227251C (es)
AP (1) AP1420A (es)
AT (1) ATE260277T1 (es)
AU (2) AU6610001A (es)
BG (1) BG66102B1 (es)
BR (1) BR0112297A (es)
CA (1) CA2414514C (es)
CR (1) CR6889A (es)
CZ (1) CZ294251B6 (es)
DE (2) DE60102160T3 (es)
DK (1) DK1300407T4 (es)
EA (1) EA005520B1 (es)
ES (1) ES2213703T5 (es)
HK (1) HK1054934A1 (es)
HU (1) HU229306B1 (es)
IL (1) IL153707A0 (es)
MX (1) MXPA03000141A (es)
NO (1) NO328499B1 (es)
OA (1) OA12300A (es)
PL (1) PL201530B1 (es)
PT (1) PT1300407E (es)
SI (1) SI1300407T2 (es)
TR (1) TR200400420T4 (es)
UA (1) UA72632C2 (es)
WO (1) WO2002000652A1 (es)
ZA (1) ZA200300644B (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
KR100751981B1 (ko) * 2000-06-27 2007-08-28 라보라토리오스 살바트, 에스.에이. 아릴알킬아민으로부터 유도된 카바메이트
JP4445704B2 (ja) * 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
UA75626C2 (en) 2000-12-28 2006-05-15 Almirall Prodesfarma Ag Quinuclidine derivatives and medicinal compositions containing the same
CN100371714C (zh) 2001-12-14 2008-02-27 塔加西普特公司 治疗中枢神经系统病症的方法和组合物
KR100944580B1 (ko) * 2001-12-20 2010-02-25 치에시 파마슈티시 에스.피.아. 1-알킬-1-아조니아비시클로[2.2.2]옥탄 카르바메이트유도체 및 이의 무스카린 수용체 길항제로서의 용도
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
CA2492121A1 (en) 2002-07-08 2004-01-15 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
US7517905B2 (en) 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CA2522071A1 (en) 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2246170B1 (es) * 2004-07-29 2007-04-01 Almirall Prodesfarma, S.A. Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007007282A2 (en) * 2005-07-11 2007-01-18 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
JP2009506037A (ja) * 2005-08-22 2009-02-12 ターガセプト，インコーポレイテッド ヘテロアリール置換ジアザトリシクロアルカン、その調製方法およびその使用方法
CA2626612A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
PE20080036A1 (es) 2005-10-21 2008-03-06 Novartis Ag Anticuerpos humanos para la interleucina-13 (il13)
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AR060607A1 (es) 2006-04-21 2008-07-02 Novartis Ag Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias.
EP1882691A1 (en) * 2006-07-26 2008-01-30 CHIESI FARMACEUTICI S.p.A. Quinuclidine derivatives as M3 antagonists
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
PT2104535E (pt) 2007-01-10 2011-03-31 Irm Llc Compostos e composições como inibidores da protease de activação de canal
AU2008212171A1 (en) * 2007-02-09 2008-08-14 Astellas Pharma Inc. Aza-bridged-ring compound
US8318935B2 (en) 2007-05-07 2012-11-27 Novartis Ag Organic compounds 75074
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
CN104193741B (zh) 2007-10-01 2016-08-24 阿尔法梅根有限责任公司 作为α7-烟碱乙酰胆碱受体配体的奎宁环-4-基甲基1H-吲哚-3-甲酸酯衍生物
EP2065385A1 (en) 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
EA017919B1 (ru) 2007-12-10 2013-04-30 Новартис Аг Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
PT2254598E (pt) * 2008-02-13 2013-10-16 Targacept Inc Combinação de agonistas nicotínicos alfa 7 e antipsicóticos
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
EP2300010B1 (en) 2008-06-10 2015-03-04 Novartis AG Pyrazine derivatives as epithelial sodium channel blockers
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
EP2391366B1 (en) 2009-01-29 2012-11-28 Novartis AG Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
WO2011022439A1 (en) 2009-08-17 2011-02-24 Intellikine, Inc. Heterocyclic compounds and uses thereof
EP2467383A1 (en) 2009-08-20 2012-06-27 Novartis AG Heterocyclic oxime compounds
CN102665715A (zh) 2009-10-22 2012-09-12 沃泰克斯药物股份有限公司 治疗囊性纤维化和其他慢性疾病的组合物
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8748433B2 (en) 2010-04-30 2014-06-10 Merck Sharp & Dohme Corp. β3 adrenergic receptor agonists
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
AP2013007103A0 (en) 2011-02-25 2013-09-30 Irm Llc Compounds and compositions as TRK inhibitors
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
US20150297604A1 (en) 2012-04-03 2015-10-22 Novartis Ag Combination Products with Tyrosine Kinase Inhibitors and their Use
MA37975B2 (fr) * 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
ES2726664T3 (es) * 2013-07-13 2019-10-08 Beijing Shuobai Pharmaceutical Co Ltd Compuestos de quinina e isómeros ópticos, procedimiento de preparación y uso médico de los mismos
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
JP6574435B2 (ja) 2014-03-07 2019-09-11 バイオクリスト ファーマスーティカルズ，インコーポレイテッドＢｉｏｃｒｙｓｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒト血漿カリクレイン阻害剤
CN106458966B (zh) 2014-04-24 2019-05-07 诺华股份有限公司 作为磷脂酰肌醇3-激酶抑制剂的吡嗪衍生物
MX2016013812A (es) 2014-04-24 2017-03-09 Novartis Ag Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa.
AU2014391605A1 (en) 2014-04-24 2016-10-27 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
US9434724B2 (en) 2014-07-11 2016-09-06 Alpharmagen, Llc Quinuclidines for modulating alpha 7 activity
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
ES2831416T3 (es) 2014-07-31 2021-06-08 Novartis Ag Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
KR20220019015A (ko) 2019-06-10 2022-02-15 노파르티스 아게 Cf, copd, 및 기관지확장증 치료를 위한 피리딘 및 피라진 유도체
WO2021038426A1 (en) 2019-08-28 2021-03-04 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
KR20230043024A (ko) 2020-07-24 2023-03-30 젠자임 코포레이션 벤글루스타트를 포함하는 제약 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287471A (en) 1964-05-05 1966-11-22 Searle & Co Pyrrolidinyl nu-phenyl-nu-benzylcarbamates
JPH0495071A (ja) 1990-08-10 1992-03-27 Kyorin Pharmaceut Co Ltd カルバミン酸誘導体
AU7545894A (en) * 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
AU685225B2 (en) * 1994-02-10 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
JPH08198751A (ja) * 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
KR100751981B1 (ko) * 2000-06-27 2007-08-28 라보라토리오스 살바트, 에스.에이. 아릴알킬아민으로부터 유도된 카바메이트
JP4445704B2 (ja) * 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
KR100944580B1 (ko) * 2001-12-20 2010-02-25 치에시 파마슈티시 에스.피.아. 1-알킬-1-아조니아비시클로[2.2.2]옥탄 카르바메이트유도체 및 이의 무스카린 수용체 길항제로서의 용도

Also Published As

Publication number Publication date
AU2001266100B2 (en) 2005-06-30
DE60102160T2 (de) 2004-09-09
CR6889A (es) 2008-08-21
EA005520B1 (ru) 2005-04-28
CN1227251C (zh) 2005-11-16
US6916828B2 (en) 2005-07-12
AP1420A (en) 2005-05-30
BG107474A (en) 2003-09-30
ATE260277T1 (de) 2004-03-15
MXPA03000141A (es) 2003-05-27
HU229306B1 (en) 2013-10-28
UA72632C2 (uk) 2005-03-15
ZA200300644B (en) 2004-02-10
US20040235887A1 (en) 2004-11-25
WO2002000652A1 (es) 2002-01-03
PL359333A1 (en) 2004-08-23
HUP0301414A3 (en) 2008-03-28
NO20026211D0 (no) 2002-12-23
BR0112297A (pt) 2003-05-06
KR20030022159A (ko) 2003-03-15
OA12300A (en) 2006-05-12
BG66102B1 (bg) 2011-04-29
CN1449396A (zh) 2003-10-15
DE60102160T3 (de) 2012-05-03
NO20026211L (no) 2003-02-26
US20040063950A1 (en) 2004-04-01
PT1300407E (pt) 2004-05-31
NO328499B1 (no) 2010-03-01
CA2414514A1 (en) 2002-01-03
EP1300407A1 (en) 2003-04-09
ES2213703T5 (es) 2011-11-02
SI1300407T2 (sl) 2011-09-30
TR200400420T4 (tr) 2004-03-22
KR100751981B1 (ko) 2007-08-28
DK1300407T4 (da) 2011-09-05
EP1300407B2 (en) 2011-06-08
CZ2003261A3 (cs) 2003-06-18
DK1300407T3 (da) 2004-03-22
CZ294251B6 (cs) 2004-11-10
JP5046465B2 (ja) 2012-10-10
ES2213703T3 (es) 2004-09-01
EA200300072A1 (ru) 2003-06-26
CA2414514C (en) 2009-12-22
AU6610001A (en) 2002-01-08
HK1054934A1 (en) 2003-12-19
SI1300407T1 (en) 2004-06-30
DE20122417U1 (de) 2005-08-04
DE60102160D1 (de) 2004-04-01
HUP0301414A2 (hu) 2003-09-29
AU2001266100B9 (en) 2005-10-06
AP2003002722A0 (en) 2003-06-30
EP1300407B1 (en) 2004-02-25
PL201530B1 (pl) 2009-04-30
JP2004501916A (ja) 2004-01-22
US7115629B2 (en) 2006-10-03

Similar Documents

Publication Publication Date Title
IL153707A0 (en) Carbamates derived from arylalkylamines
AU2001266100A1 (en) Carbamates derived from arylalkylamines
HUP0202812A3 (en) Novel bicyclonucleoside analogues
HK1050007A1 (en) Novel biarylcarboxamides
AU8860401A (en) Novel guanidinobenzamides
AU8404801A (en) Support
EG23178A (en) Carbamate condensation unit
GB0206189D0 (en) None available at present time
AU9351801A (en) Container-closure arrangement
GB0206191D0 (en) None available at present time
AU1217102A (en) Novel arylalkane-sulfonamides
AU2002359464A8 (en) Angiopioetin related factors
AU8197001A (en) Novel arylethene-sulfonamides
GB0400260D0 (en) A support
GB0022877D0 (en) Analogues
GB0206188D0 (en) None available at present time
GB0006193D0 (en) Platforms
GB9908612D0 (en) Vriable capo tasto
GB0022992D0 (en) Novel vompounds
GB0107801D0 (en) Biofilters
GB2378977B (en) A support
GB0206190D0 (en) None available at present time
GB0024408D0 (en) Support
AU145721S (en) A Pedestal
TW575176U (en) Simplified leveler

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees